Report Scope:

The current report provides details about HTA processes in countries such as U.S., Canada and U.K. This report highlights information and insights on the molecules which were recently approved in terms of regulatory and reimbursement decisions. The report includes policies, country-specific HTA activities, drug overviews, mechanisms of action, disease backgrounds, clinical evidence on safety and efficacy, regulatory scenarios, and HTA evaluation details.

Report Includes:

  • 45 tables
  • A detailed outlook on the HTA process and its approvals in major pharma industries
  • Insights into the recent HTA submissions to HTA agencies by top pharmaceutical manufacturers
  • Discussion on how HTA helps in the development of safe, and effective health policies, thereby benefitting both patient and health care providers
  • Information about the medical, social, economic and ethical issues related to the use of a health technology
  • Company profiles of market-leading players, including Janssen Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca PLC, Eli Lilly and Co., and Hofmann-La Roche Inc.